Skip to main content
TipRanks
Go Ultimate75% OFF

Bastide le Confort Medical (BLC) AI Stock Analysis

9 Followers
FR:BLC

Bastide le Confort Medical

(Paris:BLC)

Select Model
Rating:61Neutral
Price Target:EUR 21.00â–²(7.69% Upside)
Action:reiterated
Date:10/23/26

Bastide le Confort Medical scores modestly above average. The strongest support comes from financial discipline: consistent operating cash flow, expanding EBIT and EBITDA margins, and a major deleveraging that cut debt-to-equity from 5.7x to 2.3x. However, revenue has declined for two consecutive years and the eye-catching €58.1M profit appears largely non-recurring, leaving underlying earnings quality weak. The share price trend is the main drag, trading below all key moving averages with negative MACD momentum. A very low P/E offers potential value, but the absence of a dividend and the questionable earnings base temper that appeal.

Positive Factors
Long-term Revenue ExpansionThe company’s multi-year revenue expansion indicates a broader underlying demand base for home healthcare equipment and support services. Although the path is uneven, a larger revenue platform can support operating scale and continued investment in service capacity over the next several quarters.
Negative Factors
Elevated LeverageLeverage remains a significant structural constraint even after the 2026 improvement. High debt relative to equity can reduce financial flexibility, increase sensitivity to operating setbacks, and limit the capital available for service investment or other strategic priorities.

Bastide le Confort Medical (BLC) vs. iShares MSCI France ETF (EWQ)

-40%-30%-20%-10%0%10%20%FR:BLC-22.92%EWQ+2.91%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 143.84M
Dividend Yield
―
Average Volume (3M)
4,366
Price to Earnings (P/E)
2.5
Beta (1Y)
0.57
Revenue Growth
-1.79%
EPS Growth
10979.07%
Country
France
Employees
3,641
Sector
General
Sector Strength
55
Industry
Medical - Care Facilities

Bastide le Confort Medical Business Overview & Revenue Model

Company Description

Bastide Le Confort Médical SA specializes in the provision, through both sales and rentals, of medical equipment across France. The company offers a comprehensive array of items, encompassing comfort and wellness products such as specialized seating...

Bastide le Confort Medical Financial Statement Overview

Summary

A balance-sheet repair story with dependable cash generation. Operating profitability is quietly improving (EBIT up to €44.2M, 9.2% margin; EBITDA €104.9M at 21.7%), and the company generated €81.8M of operating cash and €30.8M of free cash flow despite heavy rental-equipment capex. Debt was cut sharply from €411M to €299M while equity nearly doubled to €131M, lowering leverage from 5.7x to 2.3x. Offsetting this, revenue has slipped two years running to €482M, the headline €58.1M net profit appears largely one-off (it exceeds operating profit and is unsupported by cash flow), underlying net profitability is thin, and leverage remains elevated for a capital-intensive care provider.

Income Statement

63Positive

Balance Sheet

62Positive

Cash Flow

67Positive
Financial statement breakdown
BreakdownTTMSep 2026Sep 2025Sep 2024Jun 2023Jun 2022
Income Statement
Total Revenue482.39M482.39M491.18M529.75M508.03M468.30M
Gross Profit50.87M50.87M333.00M354.44M333.73M306.80M
EBITDA104.85M104.85M102.03M107.20M98.15M89.83M
Net Income58.10M58.10M528.00K-900.00K12.05M13.68M
Balance Sheet
Total Assets575.80M575.80M661.03M647.07M657.08M632.55M
Cash, Cash Equivalents and Short-Term Investments48.21M48.21M25.49M23.62M36.71M22.13M
Total Debt299.13M299.13M411.16M408.65M427.39M419.23M
Total Liabilities444.98M444.98M589.73M566.34M568.99M545.89M
Stockholders Equity131.07M131.07M72.13M79.77M87.65M84.56M
Cash Flow
Free Cash Flow30.77M30.77M41.74M10.64M36.65M-6.51M
Operating Cash Flow81.78M81.78M101.82M66.04M90.28M46.76M
Investing Cash Flow60.08M60.08M-56.44M-43.65M-76.27M-104.74M
Financing Cash Flow-118.31M-118.31M-4.33M-35.55M-7.89M29.43M

Bastide le Confort Medical Technical Analysis

Technical Analysis SentimentNeutral
Last Price19.50

Price Trends

50DMA19.63Negative
100DMA21.29Negative
200DMA23.05Negative

Market Momentum

MACD0.13Negative
RSI53.15Neutral
STOCH69.27Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BLC, the sentiment is Neutral. The current price of 19.50 is above the 20-day moving average (MA) of 18.80, below the 50-day MA of 19.63, and below the 200-day MA of 23.05, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 53.15 is Neutral, neither overbought nor oversold. The STOCH value of 69.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:BLC.

Bastide le Confort Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

FR:BLC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:BIMFR:BIM73OutperformEUR 10.85B23.3811.01%1.07%-3.18%22.52%
FR:AIFR:AI68NeutralEUR 123.08B33.0913.42%1.58%-1.30%3.05%
FR:BOIFR:BOI65NeutralEUR 332.85M12.756.82%7.11%-1.80%35.22%
FR:BLCFR:BLC61NeutralEUR 142.60M2.4649.70%―-1.79%10979.07%
FR:ALCGMFR:ALCGM60NeutralEUR 128.64M-8.77-5.44%―-0.98%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
FR:VTRFR:VTR39UnderperformEUR 46.41M-1.29-15.20%―8.96%41.13%

* General Sector Average

Performance Comparison

-20%0%20%40%FR:BLCFR:AIFR:BIMFR:BOIFR:ALCGMFR:VTRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:BLC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:BLCBastide le Confort Medical19.50-5.75-22.77%
FR:AIAir Liquide (UK)193.2445.9531.19%
FR:BIMbioMerieux SA91.90-12.56-12.03%
FR:BOIBoiron SA19.00-6.59-25.74%
FR:ALCGMCegedim SA9.38-2.62-21.83%
FR:VTRVitura SA2.72-0.80-22.73%

Bastide le Confort Medical Corporate Events

Bastide Reports 7.5% Revenue Growth in First Quarter

Nov 12, 2026

Groupe Bastide reported first-quarter 2026-2027 revenue of €124.3 million, up 7.5% on a reported basis and 7.1% organically from restated prior-year figures. Home Healthcare Services grew 8.4% on a reported basis, while Homecare revenue increased 6.2...

Bastide Publishes 2026-2027 Financial Publication Calendar

Nov 9, 2026

On November 9, 2026, Bastide published its 2026-2027 publication calendar, with first-quarter revenue scheduled for November 12, 2026, after market close. The timetable also includes first-half revenue and results in February and March 2027, third-qu...

Bastide Publishes Annual Financial and Audit Reports

Nov 9, 2026

Bastide le Confort Medical announced the publication of its annual financial and audit reports as regulated information for Euronext compartments A, B and C. The release confirms the company’s compliance with recurring financial-reporting obligations...

Bastide Sets 2026 Meeting With Dividend and Governance Votes

Nov 6, 2026

Bastide le Confort Medical is a French public limited company; the release does not detail its products or market focus. It has called a combined general meeting for Dec. 15, 2026, to review fiscal 2026 accounts and vote on resolutions covering gover...

Bastide Reports October Share and Voting Rights Totals

Nov 5, 2026

Bastide le Confort Medical reported its share capital and voting-rights position as of October 31, 2026. The company had 7,468,749 shares, including 7,365,078 ordinary shares and 103,671 preferred shares; theoretical voting rights totaled 11,422,904,...

Bastide boosts profits, cash flow and cuts debt as home healthcare growth accelerates

Oct 21, 2026

Groupe Bastide reported 2025-2026 revenue of €482.4m, up 7.7% with organic growth of 7.9%, driven by strong momentum in higher-technology home healthcare services and solid expansion in its Home Care activity. Respiratory and diabetes segments posted...

Bastide le Confort Medical Updates Share Capital and Voting Rights Structure

Oct 8, 2026

Bastide le Confort Medical has disclosed its share capital structure as of 30 September 2026, reporting a total of 7,468,749 shares, comprising 7,365,078 ordinary shares and 103,671 preference shares. The company also reported 11,631,246 theoretical...

Bastide le Confort Medical Updates Share Capital and Voting Rights Structure

Sep 10, 2026

Bastide le Confort Medical is a French listed company specializing in medical equipment and home healthcare services, operating in the broader health and medical supplies sector. The group focuses on serving patients and care providers through a port...

Bastide lifts revenue and margins as it outperforms targets and cuts debt

Sep 3, 2026

Groupe Bastide reported 2025-2026 annual revenue from continuing operations of €482.9 million, up 7.6% year on year on a restated basis, with organic growth of 7.8% and strong contributions from respiratory and diabetes activities. Including the dive...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026